Fierce Biotech

Sarepta’s big bet on Arrowhead’s siRNA assets yields early data

Published

2 weeks ago

on

Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its decision to bet big on Arrowhead Pharmaceuticals’ pipeline.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version